xspa - XSPA STOCK NEWS

XpresSpa Group, Inc. (Nasdaq: XSPA) announced its participation in the Water Tower Research Fireside Chat Series scheduled for February 10, 2022, at 1:00 pm EST. The discussion will feature CEO Scott Milford and XpresCheck CEO Ezra Ernst, focusing on the company's business and the recent expansion of a CDC program. XpresSpa operates in health and wellness, with a portfolio that includes XpresCheck and Treat. The Company is known for its airport-based health services and spa products.

XpresSpa Group (Nasdaq: XSPA) has expanded its SARS-CoV-2 Variant Identification Program to a total of $5.6 million, extending its initial $2 million contract with the CDC. Launched in September 2021, the program aims to monitor emerging SARS-CoV-2 variants from international flights, now testing passengers from seven African countries and more. This expansion included Hartsfield-Jackson Atlanta International Airport as a testing site, increasing the number of locations to four. Effective detection of variants like Omicron has been demonstrated through this program.

XpresSpa Group, Inc. (Nasdaq: XSPA) has appointed Scott R. Milford as President and Chief Executive Officer effective January 19, 2022, succeeding Doug Satzman, who resigned for personal reasons. Milford, a pivotal figure since 2019 as COO, successfully led the CDC biosurveillance program across major U.S. airports. His extensive background includes roles at SoulCycle and Bayada. XpresSpa Chairman Bruce Bernstein expressed strong confidence in Milford’s leadership to ensure business continuity and drive sustainable growth for the company’s health and wellness brands.

XpresSpa Group, Inc. (Nasdaq: XSPA) announced on January 10, 2022, that the Board of Directors has granted an equity award to Ezra T. Ernst, related to his employment following the acquisition of HyperPointe. This award consists of stock options to purchase 1,000,000 shares of XpresSpa common stock, vesting in three equal parts over three years, contingent on continued employment. The exercise price will be based on the stock's closing price on the grant date. This strategic move aligns with XpresSpa's focus on enhancing its travel health and wellness services.

XpresSpa Group (Nasdaq: XSPA) announced its acquisition of HyperPointe for $5.5 million in cash and $1 million in stock, with potential earn-outs of up to $7.5 million. HyperPointe, a digital healthcare and data analytics agency, generated $5.5 million in revenue and $1.2 million in EBITDA in 2021. The acquisition aims to expand XpresSpa's digital health capabilities and enhance its relationship with the CDC. HyperPointe's CEO will lead XpresCheck and integrate its services, focusing on growing COVID-19 screening and testing in airports. Closing is expected in Q1 2022.

XpresSpa Group, Inc. (XSPA) reports record revenue results for Q4 and full year 2021, generating at least $27 million for Q4 and at least $71 million for the year, compared to $0.3 million and $8.4 million in 2020, respectively. The company credits robust testing volumes at XpresCheck during the holiday travel season and plans to expand services in 2022. New locations for Treat are underway, enhancing their health and wellness offerings. A long-term revenue target of $500 million by 2025 is also established.

Ginkgo Bioworks (NYSE: DNA) announced it has detected the BA.3 sublineage of the Omicron variant in North America, sourced from passengers arriving at Newark Liberty International Airport from South Africa. This detection is part of a collaborative COVID-19 surveillance program with the CDC and XpresSpa Group (Nasdaq: XSPA), involving voluntary testing of international travelers. Over 9,000 travelers have participated, with a goal of improving public health responses to emerging variants. The findings highlight the significance of airport-based monitoring in controlling virus spread.

XpresSpa Group (Nasdaq: XSPA) has launched its first Treat™ wellness center at JFK Airport's Terminal 4, aiming to cater to the evolving health priorities of travelers. This upscale facility offers services such as Covid-19 PCR tests, IV therapy, flu shots, and virtual fitness sessions. It complements Treat’s mobile app for seamless healthcare access. The new location signifies the completion of Treat’s three-phase rollout, enhancing travelers' health and wellness options. CEO Doug Satzman emphasized the importance of wellness in travel during the ongoing pandemic.

Ginkgo Bioworks (NYSE: DNA) confirmed the detection of the Omicron variant in pooled samples from air travelers arriving at Newark International Airport. This detection was part of a COVID-19 monitoring program developed in partnership with the CDC and XpresSpa Group (Nasdaq: XSPA). The program utilizes Concentric's testing infrastructure and XpresCheck's in-airport testing. Currently operational in four major airports, the initiative aims to enhance biosecurity and provide rapid public health responses. Ginkgo's Concentric has expanded its testing capabilities significantly, serving tens of millions weekly.